CT versus MR imaging of hepatocellular carcinoma: Toward improved treatment decisions

Magnetic Resonance in Medical Sciences

Volumn 11, Issue 2, 2012, Pages 75-81

  Murakami, Takamichi ^a   Okada, Masahiro ^a   Hyodo, Tomoko ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Gd EOB DTPA; Hepatocellular carcinoma; MRI

Indexed keywords

COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; FORECASTING; HUMAN; IMAGE ENHANCEMENT; LIVER CELL CARCINOMA; LIVER TUMOR; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

CARCINOMA, HEPATOCELLULAR; FORECASTING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863853144     PISSN: 13473182     EISSN: 18802206     Source Type: Journal    
DOI: 10.2463/mrms.11.75     Document Type: Review

References (30)

1. Murakami T, Onishi H, Mikami K, et al. Determining the optimal timing for early arterial phase hepatic CT imaging by measuring abdominal aortic enhancement in variable contrast injection protocols. J Comput Assist Tomogr 2006; 30:206-211.
2. Takahashi S, Murakami T, Takamura M, et al. Multi-detector row helical CT angiography of hepatic vessels: depiction with dual-arterial phase acquisition during single breath hold. Radiology 2002; 222:81-88.
3. Hashimoto K, Murakami T, Dono K, et al. Quantitative tissue blood flow measurement of the liver parenchyma: comparison between xenon CT and perfusion CT. Dig Dis Sci 2007; 52:943-949.
4. Noguchi Y, Murakami T, Kim T, et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180:455-460.
5. Imai Y, Murakami T, Yoshida S, et al. Super-paramagnetic iron oxide-enhanced MR images of hepatocellular carcinoma: correlation with histo-logical grading. Hepatology 2000; 32:205-212.
6. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4:1-9.
7. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 2007; 42:242-247.
8. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histo-logical grading and portal blood flow. Eur Radiol 2010; 20:2405-2413.
9. Okada M, Imai Y, Kim T, et al. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2010; 32:903-913.
10. Kagawa Y, Okada M, Kumano S, et al. Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gado-linium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR. J Magn Reson Imaging 2011; 33:864-872.
11. Reimer P, Rummeny EJ, Daldrup HE, et al. Clinical results with Resovist: a phase 2 clinical trial. Radiology 1995; 195:489-496.
12. Saini S, Stark DD, Hahn PF, et al. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 1987; 162(1 Pt 1):217-222.
13. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR Am J Roentgenol 1990; 155:943-950.
14. Yamamoto H, Yamashita Y, Yoshimatsu S, et al. Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging. Radiology 1995; 195:106-112.
15. Hori M, Murakami T, Kim T, et al. Detection of hypervascular hepatocellular carcinoma: comparison of SPIO-enhanced MRI with dynamic helical CT. J Comput Assist Tomogr 2002; 26:701-710.
16. Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-en-hanced MR imaging and 16-detector row CT. Radiology 2006; 238:531-541.
17. Imai Y, Murakami T, Hori M, et al. Hypervascu-lar hepatocellular carcinoma: combined dynamic MDCT and SPIO-enhanced MRI versus combined CTHA and CTAP. Hepatol Res 2008; 38:147-158.
18. Yukisawa S, Okugawa H, Masuya Y, et al. Mul-tidetector helical CT plus superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions in cirrhotic liver: a comparison with multiphase CT during hepatic arteriography. Eur J Radiol 2007; 61:279-289.
19. Kim YK, Kwak HS, Han YM, Kim CS. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and Resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography. J Comput Assist Tomogr 2007; 31:702-711.
20. Hamm B, Staks T, Muähler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792.
21. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroen-terol 2009; 44:793-798.
22. Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol 2003; 13:2688-2698.
23. Brasch RC. New directions in the development of MR imaging contrast media. Radiology 1992; 183: 1-11.
24. Di Martino M, Marin D, Guerrisi A, et al. Intra-individual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetec-tor CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010; 256: 806-816.
25. Park G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic ecacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Ra-diol 2010; 83:1010-1016.
26. Hayashi M, Matsui O, Ueda K, et al. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002; 225:143-149.
27. Hyodo T, Okada M, Murakami T, et al. Hypovas-cular nodules presented with hypointensity on the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI in cirrhotic patients: risk factors for hyper-vascularization. 70th J Japanese Radiological Society 2011; S342-S343.
28. Tsuboyama T, Onishi H, Kim T, et al. Hepatocel-lular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correla-tion with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255:824-833.
29. Katsube T, Okada M, Kumano S, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 2011; 46:277-283.
30. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009; 192:1675-1681.